You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline characteristics of the EuroSIDA patients, included in the study after January 1 st , 2001 and according to the region of residence

From: Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study

   SE WCE NE ECE EE AR p
   1059 1290 923 1366 1964 495  
N (% of total)         
Gender Male 799 (75.5) 992 (76.9) 702 (76.1) 968 (70.9) 1103 (56.2) 307 (62.0) <.0001
Ethnic origin White 952 (90.0) 911 (76.7) 749 (81.9) 1358 (99.6) 1958 (99.9) 488 (98.6) <.0001
Exposure Group Homosexual 7426 (40.2) 566 (43.9) 473 (51.3) 508 (37.2) 149 (7.6) 126 (25.5) <.0001
  IDU 188 (17.8) 128 (9.9) 86 (9.9) 345 (25.3) 923 (47.0) 62 (12.5)  
  Heterosexual 359 (33.9) 404 (31.3) 290 (31.4) 410 (30.0) 791 (40.3) 291 (58.8)  
Treatment History Naïve 253 (23.9) 183 (14.2) 145 (15.7) 259 (19.0) 1200 (61.1) 82 (16.6) <.0001
  cART 763 (72.0) 1035 (80.2) 744 (80.6) 1016 (74.4) 632 (32.2) 396 (80.0)  
Hepatitis B surface antigen status positive 45 (4.3) 58 (4.5) 35 (3.8) 60 (4.4) 107 (5.5) 26 (5.3) .003
  negative 827 (78.1) 996 (77.2) 742 (80.4) 1115 (81.6) 1562 (79.5) 357 (72.1)  
  unknown 187 (17.7) 236 (18.3) 146 (15.8) 191 (14.0) 295 (15.0) 112 (22.6)  
Hepatitis C antibody status positive 174 (16.4) 155 (12.0) 81 (8.8) 352 (25.8) 950 (48.4) 91 (18.4) <.0001
  negative 688 (65.0) 874 (67.8) 662 (71.6) 831 (60.8) 666 (33.9) 295 (59.6)  
  unknown 197 (18.6) 261 (20.2) 180 (19.5) 183 (13.4) 348 (17.7) 109 (22.0)  
Previous AIDS diagnosis yes 180 (17.0) 352 (27.3) 187 (20.3) 312 (19.9) 391 (19.9) 101 (32.5) <.0001
Median (IQR)        
Age 39 (33–46) 42 (36–49) 42 (36–50) 35 (29–42) 30 (26–36) 36 (31–43) <.0001
CD4-cell count/mm3 1 434 (293–636) 447 (305–628) 432 (310–610) 369 (245–524) 415 (267–575) 346 (199–518) <.0001
HIV-RNA (log10) copies/ml2 2.05 (1.70-4.08) 1.70 (1.70-3.33) 1.70 (1.60-3.28) 2.33 (1.70-3.79) 3.48 (2.60-4.58) 2.19 (1.70-4.00) <.0001
Baseline date 1/06 (11/03-6/06) 1/06 (11/03-8/06) 1/06 (11/03-6/08) 11/05 (1/02-6/08) 1/06 (2/04-6/08) 2/06 (1/03-6/06) <.0001
  1. Baseline date defined as the date of enrolment into the EuroSIDA study.
  2. IDU, injection drug user; cART, combination antiretroviral therapy; HIV-RNA, viral load;
  3. SE, Southern Europe: Greece, Israel, Italy, Portugal, Spain; WCE, West Central Europe: Austria, Belgium, France, South Germany, Luxembourg, Switzerland; NE, Northern Europe: Denmark, Finland, North Germany, Ireland, the Netherlands, Norway, Sweden, the United Kingdom; ECE, East Central Europe: Bulgaria, Croatia, the Czech Republic, Hungary, Poland, Romania, Serbia and Slovakia; EE, Eastern Europe: Belarus, Estonia, Latvia, Lithuania, the Russian Federation and the Ukraine; AR, Argentina.
  4. 1 N (%) CD4-cell count measurements were missing for 33 (3.1), 36 (2.8), 26 (2.8), 67 (4.69), 418(21.3) and 104 (21.0) in SE, WCE, NE, ECE, EE and AR respectively.
  5. 2 N (%) HIV-RNA measurements were missing for: 52 (4.9), 49 (3.8), 21 (2.3), 252 (18.5), 1289 (65.6) and 132 (26.7) in SE, WCE, NE, ECE, EE and AR respectively.